OHR Pharmaceutical (OHRP) Stock Price, News & Analysis

Company Overview

OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Key Stats

• Today's Range: N/A
• 50-Day Range: $5.39 to $9.07
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 180,228 shs
• Market Capitalization: $1.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OHRP Stock Analysis - Frequently Asked Questions

How were OHR Pharmaceutical's earnings last quarter?

OHR Pharmaceutical Inc (NASDAQ:OHRP) issued its earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.20) earnings per share for the quarter.

When did OHR Pharmaceutical's stock split?

OHR Pharmaceutical's stock reverse split before market open on Monday, February 4th 2019. The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 1st 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of OHR Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OHR Pharmaceutical investors own include Actinium Pharmaceuticals (ATNM), TherapeuticsMD (TXMD), IVERIC bio (OPHT), Cytori Therapeutics (CYTX), Novavax (NVAX), Immunomedics (IMMU) and Synergy Pharmaceuticals (SGYP).

Company Calendar

• Last Earnings: 8/14/2018
• Today: 12/21/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OHRP
• CUSIP: N/A
• CIK: 1173281
• Web: www.ohrpharmaceutical.com
• Phone: 212-682-8452
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-13,230,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -75.46%
• Return on Assets: -71.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.73
• Quick Ratio: 3.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.86 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,829,000
• Free Float: N/A
• Market Cap: $1.08 million
• Optionable: Not Optionable
• Beta: 0.84